Ultrasound-Responsive Smart Hydrogel for Diabetic Wound Healing

Beyond passive dressings: a Peking University team develops an ultrasound-responsive hydrogel for on-demand smart therapy of diabetic wounds.

1. The core challenge: why do diabetic wounds heal so poorly?

Diabetic wounds, particularly foot ulcers, are a major clinical challenge because of a complex vicious cycle: a persistent hyperglycemic environment leads to neuropathy, microvascular dysfunction, and chronic inflammation. Conventional treatments often target the wound locally but overlook a key upstream regulator, the sensory nerves.

Calcitonin gene-related peptide (CGRP), secreted by nerve endings, is a crucial signal that switches the wound from the inflammatory phase to the repair phase. However, diabetic neuropathy and harmful reactive oxygen species (ROS) at the wound site jointly block this vital neuro-immune communication. Furthermore, standard drugs or dressings lack precise release control, so active components such as CGRP degrade quickly in the complex wound environment and fail to provide stable, long-term healing.

2. The innovative solution: the ultrasound-responsive intelligent hydrogel platform MCF@CA

To address these challenges, a team led by Professor Shumin Wang and Researcher Xiaolong Liang from the Department of Ultrasound at Peking University Third Hospital published a breakthrough study in Advanced Science in January 2026. They designed and built an ultrasound-controlled release hydrogel delivery system named MCF@CA, featuring an integrated four-pronged strategy:

Dual-effect drug system. The team covalently linked CGRP (for neuro-immune regulation) with manganese porphyrin (MnP) (for scavenging harmful ROS) to form a single composite molecule (MnP-CGRP), achieving synergy at the source.

Precision-guided targeted delivery. This composite self-assembles into nanoparticles (MCF NPs), which are then equipped with folate (FA) targeting ligands on their surface. These ligands specifically recognize inflammatory cells at the wound site, significantly enhancing drug accumulation and delivery efficiency to the lesion.

On-demand ultrasound-controlled release. The targeted nanoparticles are loaded into a sodium alginate hydrogel. Upon exposure to external ultrasound, the cross-linked structure of this hydrogel degrades in a controlled manner, enabling precise, on-demand release of the encapsulated drugs. Clinicians can personalize treatment by adjusting ultrasound parameters (intensity, duration) to control the release rate and dosage based on the wound's specific phase (for example, acute inflammation versus granulation), offering unprecedented therapeutic flexibility.

Open and compatible universal platform. This hydrogel system serves as a foundational carrier that could, in the future, be loaded with various therapeutic agents (for example, antibiotics, growth factors), paving the way for a series of products for different indications. In addition, the hydrogel is injectable, allowing it to conform perfectly to irregular wound surfaces such as joints and toes.

3. Technical validation and efficacy

Experimental results confirmed the excellent biocompatibility of the MCF@CA system. In diabetic animal models, the system demonstrated outstanding wound-healing capabilities:

Precise spatiotemporal control, achieved through ultrasound, enabling targeted drug release.

Synergistic action, concurrently exerting neuro-immune modulation (promoting CGRP signaling) and ROS scavenging, effectively breaking the inflammatory cycle.

Enhanced repair, significantly accelerating wound closure, promoting angiogenesis, and facilitating organized collagen deposition.

4. Significance and future prospects

This research marks a significant step from passive covering to active intelligent regulation in diabetic wound therapy. The MCF@CA system integrates diagnosis (ultrasound imaging) and treatment (controlled drug release), giving clinicians a smart tool for real-time intervention.

It not only offers a novel therapeutic approach for chronic diabetic wounds but also, thanks to its modular and scalable design, holds promise as a universal platform for other hard-to-heal wounds (for example, burns and venous ulcers). The team suggests that future work should focus on developing a series of products adapted to different scenarios based on this open platform, ultimately improving the precision and effectiveness of diabetic wound treatment and reducing amputation risks.

Conclusion. This achievement from the Peking University team is a model of deep integration between materials science, nanomedicine, ultrasound engineering, and clinical medicine. It presents a highly translatable Chinese solution to the global challenge of diabetic foot ulcers.